晚期宫颈癌患者应用紫杉醇联合不同铂类同步放化疗的效果分析

Effect analysis of paclitaxel combined with different platinum chemoradiotherapy in patients with advanced cervicalcancer

目的探究晚期宫颈癌患者应用紫杉醇联合不同铂类同步放化疗的临床效果。方法选择晚期宫颈癌患者54例为研究对象,采用随机数字表法分为奥沙利铂(L-OHP)组(27例)及顺铂(DDP)组(27例)。L-OHP组采用紫杉醇联合L-OHP治疗,DDP组采用紫杉醇联合DDP治疗。比较两组患者的临床疗效、毒性反应、免疫功能及生存情况。结果L-OHP组脱发、骨髓抑制发生率分别为33.33%、18.52%,均低于DDP组的62.96%、44.44%,差异有统计学意义(P<0.05)。两组临床疗效、三年生存率、毒副反应发生率、免疫功能比较,差异无统计学意义(P>0.05)。结论紫杉醇联合L-OHP与其联合DDP的同步放化疗效果在晚期宫颈癌中较为相似,总有效率均可达到60%以上。

Objective To investigate the clinical effect of paclitaxel combined with different platinum chemoradiotherapy in patients with advanced cervical cancer.Methods 54 patients with advanced cervical cancer were selected as the study objects and were divided into an oxaliplatin(L-OHP)group(27 cases)and a cisplatin(DDP)group(27 cases)by random number table method.L-OHP group was treated with paclitaxel combined with L-OHP,and the DDP group was treated with paclitaxel combined with DDP.The clinical efficacy,toxicity,immune function and survival of the two groups were compared.Results The incidence of alopecia and myelosuppression in the L-0HP group were 33.33%and 18.52%,respectively,lower than 62.96%and 44.44%in the DDP group,the differences were statistically significant(P<o.o5).There were no significant differences in clinical efficacy,three year survival rate,incidence of toxic and side effects,and immune function between the two groups(P>0.05).Conclusion The effect of concurrent chemoradiotherapy of paclitaxel combined with L-OHP and DDP is similar in advanced cervical cancer,and the total effective rate can reach more than 60%.